Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 650, Los Angeles, CA 90095, USA.
J Neurooncol. 2012 Jan;106(1):111-9. doi: 10.1007/s11060-011-0638-x. Epub 2011 Jun 25.
The purpose of the current study was to quantify the reduction in T2 signal abnormality accompanying administration of the anti-angiogenic drug bevacizumab in recurrent glioblastoma (GBM) patients using a voxel-wise differential quantitative T2 (DQT2) mapping technique. Twenty-six patients with recurrent GBM treated with bevacizumab were scanned before and 4-6 weeks after treatment on a 1.5T clinical MR scanner. Quantitative T2 maps were created from proton density and T2-weighted images acquired using a standard multi-echo fast-spin echo sequence. T2 maps after treatment were co-registered with T2 maps prior to treatment in the same patient, and then voxel-wise subtraction was performed to create DQT2 maps for each patient. Results suggest DQT2 maps allow visualization and quantification of voxel-wise T2 changes resulting from anti-VEGF therapy. Results demonstrated a significant decrease in T2 within pre-treatment T2 abnormal regions (mean reduction = 49.4 ms at 1.5T) following anti-VEGF treatment (Wilcoxon signed rank test, P < 0.0001). An elevated residual, post-treatment, median T2 was predictive of both progression-free (Log-rank, P = 0.0074) and overall survival (Log-rank, P = 0.0393).
本研究的目的是使用基于体素的定量 T2 差异（DQT2）映射技术，量化抗血管生成药物贝伐单抗治疗复发性胶质母细胞瘤（GBM）患者后 T2 信号异常的减少。对 26 例接受贝伐单抗治疗的复发性 GBM 患者，在 1.5T 临床磁共振扫描仪上，于治疗前和治疗后 4-6 周进行扫描。使用标准的多回波快速自旋回波序列，从质子密度和 T2 加权图像中创建定量 T2 图。治疗后的 T2 图与同一患者治疗前的 T2 图进行配准，然后对每个患者进行体素减法，以创建 DQT2 图。结果表明，DQT2 图可用于可视化和量化抗 VEGF 治疗引起的体素 T2 变化。结果表明，在接受抗 VEGF 治疗后，预处理 T2 异常区域内的 T2 明显降低（1.5T 时平均降低 49.4ms）（Wilcoxon 符号秩检验，P <0.0001）。治疗后残留的中位 T2 升高与无进展生存期（Log-rank，P = 0.0074）和总生存期（Log-rank，P = 0.0393）均有关。
